ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

RDHL Redhill Biopharma Ltd

0.5302
0.003 (0.57%)
Pre Market
Last Updated: 06:06:05
Delayed by 15 minutes

Period:

Draw Mode:

Volume 5,701
Bid Price 0.5276
Ask Price 0.5302
News -
Share Name Share Symbol Market Stock Type
Redhill Biopharma Ltd RDHL NASDAQ Depository Receipt
  Price Change Price Change % Share Price Last Trade
0.003 0.57% 0.5302 06:06:05
Open Price Low Price High Price Close Price Previous Close
0.5272
Trades Shares Traded Average Volume
83 5,701 -
Last Trade Type Quantity Price Currency
06:06:05 formt 309  0.5302 USD

Redhill Biopharma Ltd Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
0 0.00 - 61.8M -71.67M - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

News Redhill Biopharma

Date Time Source Heading
2/20/202415:05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2/20/202406:01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2/20/202406:00PR Newswire (US)RedHill's Opaganib Protects Against Radiation-Induced Lung..
2/16/202407:54Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]
2/15/202423:15Edgar (US Regulatory)Form EFFECT - Notice of Effectiveness
2/13/202415:05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2/02/202415:10Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial..
2/01/202409:22Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial..
1/26/202411:50Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and..
1/26/202411:46PR Newswire (US)RedHill Biopharma Announces Closing of $8 Million Registered..
1/26/202408:31Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and..
1/26/202408:29Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No RDHL Message Board. Create One! See More Posts on RDHL Message Board See More Message Board Posts

RDHL Historical

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.000.000.000.0000.000.00%
1 Month0.000.000.000.0000.000.00%
3 Months0.000.000.000.0000.000.00%
6 Months0.000.000.000.0000.000.00%
1 Year0.000.000.000.0000.000.00%
3 Years0.000.000.000.0000.000.00%
5 Years0.000.000.000.0000.000.00%

Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults, Talicia for the treatment of Helicobacter pylori infection in adults, and Aemcolo for the treatment of travelers' diarrhea in adults. Its key clinical late-stage development programs include RHB-104 for Crohn's disease; RHB-204, for pulmonary nontuberculous mycobacteria infections; RHB-102 (Bekinda) with positive results from a first Phase 3 study for acute gastroenteritis and gastritis; Opaganib (Yeliva); RHB-106, an encapsulated bowel preparation and RHB-107, a Phase 2-stage serine protease inhibitor targeting cancer and inflammatory gastrointestinal diseases.

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: 1-888-992-3836 | help@advfn.com